Table 2.
Expression of miR-17-5p and significant clinicopathological variables independent prognostic impact on BF (Cox regression analyses, n = 535).
| Characteristic | BF (200 events) | |||
|---|---|---|---|---|
| Model 1 | Model 2 | |||
| HR (95% CI) | p | HR (95% CI) | p | |
| ISUP Grade Group | NS | NS | ||
| Preop. PSA | < 0.001 | < 0.001 | ||
| PSA < 10 | 1 | 1 | ||
| PSA > 10 | 1.94 (1.39–2.73) | 1.88 (1.34–2.64) | ||
| Tumor Size | 0.042 | 0.030 | ||
| ≤ 20 mm | 1 | 1 | ||
| > 20 mm | 1.45 (1.01–2.08) | 1.49 (1.04–2.14) | ||
| pT-stage | < 0.001 | < 0.001 | ||
| pT2 | 1 | 1 | ||
| pT3a | 1.63 (1.10–2.43) | 0.016 | 1.61 (1.08–2.40) | 0.019 |
| pT3b | 3.41 (2.14–5.42) | < 0.001 | 3.39 (2.12–5.42) | < 0.001 |
| pN-stage | NE | NE | ||
| PNI | 0.014 | 0.026 | ||
| No | 1 | 1 | ||
| Yes | 1.58 (1.10–2.27) | 1.53 (1.05–2.21) | ||
| LVI | NS | NS | ||
| Margin | NS | NS | ||
| PCM | NS | NS | ||
| miR-17-5p in TE* | < 0.001 | NE | ||
| Low expression | 1 | |||
| High expression | 1.87 (1.32–2.67) | |||
| miR-17-5p in TS* | NS | NE | ||
| miR-17-5p in TE + TS* | NE | 0.004 | ||
| Low/low expression | 1 | |||
| Mixed expression | 1.03 (0.62–1.70) | 0.916 | ||
| High/high expression | 1.81 (1.15–2.85) | 0.011 | ||
Multivariate analysis with p ≤ 0.05 from the univariate analyses (Table 1 and Supplementary Table S1).
*The variables TE and TS was included in the same model, while the TE + TS variable was in a separate model.
Abbreviations: BF = biochemical failure; CF = clinical failure; LVI = lympho-vascular infiltration; NE = not entered; NS = not significant; p = p-value; PAM = positive apical margin; PCM = positive circumferent margin; PNI = perineural infiltration; Preop = preoperative; PSA = prostate specific antigen; TE = tumor epithelium; TS = tumor stroma.